Grant: Master's Award: Canada Graduate Scholarships
University of Calgary
$27,000.00
Enhancing Dendritic Cell Cross-Presentation Through APOL7C for Cancer Immunotherapy
EF 2024-25
Résumé
Harnessing Dendritic Cells to Boost Cancer ImmunityOur immune system is constantly protecting us from dangers like infections and cancer. A key player in this system is a type of immune cell called dendritic cells (DCs). These cells identify invaders, such as cancer cells, and trigger immune responses by presenting pieces of the invader to other immune cells, leading to their destruction. This process, known as cross-presentation (XP), is essential in fighting cancer. My research focuses on a specific protein called APOL7C, which is involved in enhancing XP. APOL7C helps DCs break down dangerous material, such as tumor cells, and show it to the immune system. However, the way APOL7C is recruited to where it is needed inside these cells is not fully understood. One important player in this process is a receptor called DNGR-1, which is located on the surface of DCs and helps detect cancer cells. Upon recognizing these dying cells, DNGR-1 may then help guide APOL7C to the right place inside the cell to enhance the immune response. By better understanding how this works, we hope to find new ways for the immune system to more effectively target and destroy cancer cells. This project aims to investigate (I) how DNGR-1 recruits APOL7C and (II) whether we can use this knowledge to create a new type of cancer therapy. We hope to engineer immune cells that are better equipped to detect and destroy cancer, potentially leading to more effective immunotherapies. My CIHR CGS will therefore have a significant impact on advancing our understanding of the immune system ability to target and eliminate cancer, offering a novel approach to cancer treatment by leveraging the body own immune system for a more precise and durable therapeutic response.
Programme
Master's Award: Canada Graduate Scholarships
Bénéficiaire
Emplacement
Alberta, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
530383
Name
Wood Cassandra
Region
Alberta
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Enhancing Dendritic Cell Cross-Presentation Through APOL7C for Cancer Immunotherapy
Programtype2
Studentship Programs
Orgnameinp2
University of Calgary
Cihramount2
$27,000
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Anti-Tumour Immunity; Apol7c; Cancer Immunity; Cancer Immunotherapy; Cd8(+) T Cells; Chimeric Antigen Receptors; Cross-Presentation; Dendritic Cells; Dngr-1/Clec9a; Phagosomes
Abstract
Harnessing Dendritic Cells to Boost Cancer ImmunityOur immune system is constantly protecting us from dangers like infections and cancer. A key player in this system is a type of immune cell called dendritic cells (DCs). These cells identify invaders, such as cancer cells, and trigger immune responses by presenting pieces of the invader to other immune cells, leading to their destruction. This process, known as cross-presentation (XP), is essential in fighting cancer. My research focuses on a specific protein called APOL7C, which is involved in enhancing XP. APOL7C helps DCs break down dangerous material, such as tumor cells, and show it to the immune system. However, the way APOL7C is recruited to where it is needed inside these cells is not fully understood. One important player in this process is a receptor called DNGR-1, which is located on the surface of DCs and helps detect cancer cells. Upon recognizing these dying cells, DNGR-1 may then help guide APOL7C to the right place inside the cell to enhance the immune response. By better understanding how this works, we hope to find new ways for the immune system to more effectively target and destroy cancer cells. This project aims to investigate (I) how DNGR-1 recruits APOL7C and (II) whether we can use this knowledge to create a new type of cancer therapy. We hope to engineer immune cells that are better equipped to detect and destroy cancer, potentially leading to more effective immunotherapies. My CIHR CGS will therefore have a significant impact on advancing our understanding of the immune system ability to target and eliminate cancer, offering a novel approach to cancer treatment by leveraging the body own immune system for a more precise and durable therapeutic response.
Competitiondate
202412
Approvedterm2
1 yr 0 mth
Pinamesdelim
Wood, Cassandra
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $27,000~ $0~